Mohs Micrographic Surgery (MMS) is widely employed in the treatment of non-melanoma skin cancer and is a preferred treatment for many cutaneous malignancies, particularly in high risk locations and tumors [1,2]. It has also been used in the narrow excision of malignant melanoma with local control rates equivalent to standard margins [3] . It has gained acceptance in the treatment of noninvasive melanoma where standard 0.5 cm margins may be inadequate for local control [4]. The frozen section processing used in MMS has been assumed by some to be inadequate in assessing melanocyte populations or residual melanoma within excision margins. This difficulty has likely led to a majority of surgeons with fellowship training to process margins with slow, permanent hematoxylin and eosin sections ("slowmohs") or to simply resort to standard 0.5, 1.0, or 2.0 cm margins with traditional excision and outside pathology confirmation of clear margins. A recent survey of practicing fellowship-trained Mohs surgeons revealed roughly one-third (35.9%) of Mohs surgeons felt comfortable interpreting MART-1 immunostains, and far fewer were actually performing immunostains in their labs [5]. Some Mohs surgeons currently refer melanoma to a colleague experienced in processing and reading melanoma with available rapid immunostaining. The development of rapid immunohistochemistry, which can be implemented into a traditional frozen section laboratory, has greatly improved the ease of interpreting margins in the excision of melanoma. Although the process is considerably more complicated than staining with H&E or Toluidine Blue (T-Blue), it easily falls within the skill-set and equipment of most busy frozen section laboratories. The additional cost of biologic reagents may be fully recovered by proper billing of immunohistochemical laboratory work and interpretation of slides.
Introduction
Multiple immunohistochemical staining protocols for the melanoma antigen recognized by T-cells (MART-1) using frozen sections have been developed and presented over the last decade. Historically, melanoma was processed with en-face frozen H&E staining, or with permanent paraffin sections requiring overnight processing and multiple days between each Mohs layer. In 2004, Bricca [6] and associates presented a reproducible 1-hour MART-1 protocol for melanoma frozen sections. Later, Asadi [7] and colleagues reported a modified 20-minute protocol. Currently, the American College of Mohs Surgery has a suggested modified protocol available to its members online [8] . The third protocol resembles a combination of the Bricca and Asadi protocols.
While all three methods produce reliable staining, each has its respective strengths and weaknesses. The 1-hour protocol gives consistent dependable results, however the lab processing time is dramatically longer than that of a routine section stained with H&E. The 20-minute rapid protocol requires considerably less time, but demands the lab technician's full attention, excluding other casework. The clarity of the slides produced using this rapid protocol also may contain excessive chromogen "chatter" where much of the melanocytic detail may be lost. The weakness inherent in the Mohs College protocol is that it is only available to its members, and remains unpublished in the public domain.
We present an experimental 35-minute MART-1 staining protocol for melanoma frozen sections that combines the best of the previously presented protocols, while eliminating many of the aforementioned obstacles ( Tables 1 and 2 ). In addition, we propose the use of Table 1 . Happy medium protocol. Steps in this section take place in a humidity chamber-to achieve humidification by pouring 90˚C -100˚C (boiling) water in the chamber beneath the slides and shutting the lid. + We perform the counterstain in a linear automated stainer-can be hand dipped using the same time increments.
ǂ If you require bluing in the H & E protocol, it will need to be added here.
T-Blue as a reasonable alternative to the standard use of Hematoxylin, as a counterstain, although Hematoxylin may certainly be used. We have also substituted T-Blue in all of the published protocols with reproducible staining compatible with the suggested reagents. Lastly, we suggest the implementation of an automated stainer during the counterstaining process for consistent, reproducible, easily readable slides. As an added benefit, the use of the automated stainer unburdens the histo-technician freeing him/her for additional lab work.
We have also found inexpensive ways to implement this protocol. In addition to readily available supplies, we were able to utilize commonly found items in lieu of more costly lab equipment. Our 60˚C hot plate is a toaster oven in combination with a certified thermometer. A small percolator of boiling water replaced the need for an additional 100˚C hot plate that is used in the humidification process. Likewise, we eliminated the problematic issue of obtaining negative control tissue, that can be costly and difficult to store, by utilizing non-melanoma tissue from cases being treated at the same time as the melanoma(s). Positive/negative controls are subjected to the same protocol as the melanoma tissue, replacing the MART-1 antibody with distilled water for the negative control. By setting this as our standard operating procedure, we were able to satisfy CLIA requirements for positive/negative controls.
Lastly, we introduced a linear automated stainer to perform the counterstain. With our stainer set with TBlue, it delivers a pleasing alternative to the traditional Hematoxylin counterstain. This simple step provides more opportunity for the histotechnician to continue processing other tissue while not sacrificing reproducible slide quality.
Conclusion
Most practices currently performing standard Mohs processing are well equipped to add rapid MART-1 immunostaining regardless of training or experience. Additional publications have elucidated simple interpretation of normal melanocytes, atypical melanocytic proliferations, or malignant melanoma and other cells which will stain positive with MART-1 [9, 10] . Processing melanoma with MART-1 staining, due to the complexity and intensive hands-on nature of the staining process, can initially be a rate-limiting event, but may quickly become routine, reproducible, and valuable in the treatment of melanoma. As most practices have a single histotech, multi-tasking is essential to the efficiency and flow of the lab. Finding efficient, reproducible practices are central to the continued adeptness of the Mohs laboratory. Our experience with this protocol has produced well-defined, consistent readable slides in which the melanocytic detail is markedly distinct (Figure 1) . Counterstaining with
